Padcev could also be protected for older sufferers with urothelial carcinoma, with diminished beginning doses resulting in fewer uncomfortable side effects.
Remedy with Padcev (enfortumab vedotin) for urothelial carcinoma, a kind of bladder most cancers, could not trigger extreme or sudden uncomfortable side effects notably in sufferers aged 80 years and older, latest examine findings counsel.
Of notice, outcomes from this examine, which had been offered on the 2025 American Society of Scientific Oncology Genitourinary Cancers Symposium, had been from a small affected person inhabitants and based mostly on an evaluation of sufferers after they had been handled.
Extra sufferers aged 85 years and older acquired upfront Padcev dose discount. There have been fewer grade 2/3 (reasonable to extreme) treatment-related uncomfortable side effects with decrease beginning doses of Padcev.
“Up-front dose discount of [Padcev] could also be an excellent technique to mitigate [treatment-related side effect] danger,” the researchers wrote within the summary.
Glossary:
Ocular signs: associated to the eyes or imaginative and prescient.
Neuropathy: harm to the nerves or the peripheral nervous system, inflicting ache, numbness, muscle weak spot, tingling and lack of sensation.
Pruritus: itching.
Irregular electrolytes: an imbalance of drugs equivalent to sodium, potassium, chloride, magnesium, calcium and phosphate. This may be attributable to dehydration or overhydration, hormonal imbalances, kidney illness, medicines or different components.
The median age of the 26 sufferers included on this examine was 86.5 years. The sufferers had been categorized by age: group 1 had been aged 80 to 84 years (38.5%), group 2 had been aged 85 to 89 years (46.2%) and group 3 had been aged 90 years and older (15.4%). Concerning remedy, 69.2% of sufferers had been handled with Padcev monotherapy and 30.8% had been handled with Padcev plus Keytruda (pembrolizumab). Practically all sufferers handled with Padcev monotherapy — 88.9% — beforehand acquired a PD-1/PD-L1 inhibitor.
At information cutoff, 27% of sufferers had been nonetheless handled with Padcev, with a median variety of Padcev infusions of 10.5 and a median variety of weeks on the remedy of 19.5.
Beginning Doses and Toxicity
Nearly all of sufferers in group 1 acquired an Padcev beginning dose of 1 mg/kg (70%) in contrast with 1.25 mg/kg (30%). In group 2, most sufferers acquired a beginning dose of 0.75 mg/kg (41.7%), adopted by 1 mg/kg (25%), 1.25 mg/kg (16.7%) and 0.5 mg/kg (16.7%). Half of the sufferers in group 3 acquired a beginning dose of 1 mg/kg (50%), adopted by 1.25 mg/kg (25%) then 0.5 mg/kg (25%).
After beginning remedy with Padcev, 50% of sufferers had a minimum of one dose discount, 42.3% had a minimum of one delayed dose and 30.8% had discontinued Padcev as a result of treatment-related uncomfortable side effects.
For toxicity, the commonest severity was grade 1 (delicate; 30.8%), adopted by grade 0 (no uncomfortable side effects occurred; 26.9%), grade 2 (26.9%) and grade 3 (15.4%). No sufferers within the examine skilled grade 4/5 (life-threatening or inflicting loss of life) toxicities.
When assessed by beginning dose, the proportion of sufferers with treatment-related uncomfortable side effects associated to Padcev was highest in those that acquired 1 mg/kg (46.2%), adopted by 1.25 mg/kg (23.1%), 0.75 mg/kg (19.2%) and 0.5 mg/kg (11.5%).
Among the particular treatment-related uncomfortable side effects that occurred within the examine embody ocular signs (19.2%), neuropathy (34.6%) and nausea/diarrhea (3.8% every). Moreover, pruritus, rash, irregular electrolytes and fatigue occurred at a charge of 15.4% every.
Background and Strategies
On this evaluation, researchers reviewed information from sufferers with urothelial carcinoma who had been handled with both Padcev monotherapy or Padcev plus Keytruda. Sufferers had been aged 80 years or older when beginning remedy with Padcev and needed to obtain a minimum of one dose of Padcev.
The antibody drug conjugate Padcev was accredited by the FDA in July 2021 as monotherapy for regionally superior or metastatic urothelial most cancers. The mix of Padcev and Keytruda was granted accelerated approval by the FDA in April 2023 for regionally superior or metastatic urothelial most cancers. This was transformed to a full approval in December 2023.
Throughout the background part of the summary, researchers famous that Padcev was related to a number of toxicities, “that are largely nonoverlapping with these of [Keytruda],” they wrote.
Based mostly on findings from the EV-302 examine, beforehand printed in The New England Journal of Drugs, 55.9% of sufferers skilled grade 3 or larger treatment-related uncomfortable side effects. Remedy discontinuation occurred in 35% of sufferers receiving Padcev plus Keytruda.
“[Patients] aged 80 years or older (i.e., the ultra-elderly) are a particular inhabitants who could also be notably weak to [Padcev] toxicity,” the researchers wrote within the summary.
References:
- “Actual world toxicity profile of enfortumab vedotin (EV) with or with out pembrolizumab (P) in extremely aged urothelial carcinoma (UC) sufferers (pts).” Dr. Nataliya Mar, et al. J Clin Oncol.
- “Enfortumab vedotin and pembrolizumab in untreated superior urothelial most cancers.” Dr. Thomas Powles, et al. N Engl J Med.
For extra information on most cancers updates, analysis and training, don’t neglect to subscribe to CURE®’s newsletters right here.
